Project Grant R56HL171603
Award Date
9/17/24
Completion Date
8/31/25
Dollars Obligated
$753K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This $203,974 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research project to investigate the effects of normal and diseased extracellular matrix (ECM) on the self-renewal and differentiation of airway basal epithelial cells. The project leverages novel tools developed by the co-PIs, including "inside-out" airway organoids and ECM hydrogels derived from normal and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,831,848 to the University of Rochester to investigate how neonatal microbiome colonization impacts lung immunity and regeneration. The research aims to elucidate how early-life microbial dysbiosis remodels the developmental program in lung-resident lymphocytes and epithelial cells, contributing to chronic respiratory disease. Key...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $802,500 Cooperative Agreement grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports the construction of a multi-scale 3D AI-powered map of genetic factors and cellular interactions driving normal and aberrant lung development in childhood interstitial lung disease (CHILD). The project will leverage single-cell and spatial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $844,386 to support research on the genetic landscape of childhood interstitial and diffuse lung diseases (CHILD). The key objectives are to: 1) Define molecular profiles of 300 CHILD lung biopsy samples to identify patient clusters with similar underlying causes, 2) Analyze whole exome sequence data from 400 children with...
This $600,761 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the role of the NKG2D receptor and its ligands in driving lung inflammation and development of bronchopulmonary dysplasia (BPD) in preterm infants. The key objectives are to: 1) Investigate the contribution of NKG2D+ lung lymphocytes (gamma-delta T cells and NK cells) to LPS- and hyperoxia-induced lung...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $773,916 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The 5-year grant, which runs from August 2024 to June 2029, aims to create and validate a tool to calculate the contribution of each phenotype of bronchopulmonary dysplasia (BPD) to elevated breathing effort, known as the work of breathing (WOB), in premature neonates. The research...
This $392,882 Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research by Dr. Brandon Smith at The Johns Hopkins University to address racial disparities in chronic lung disease (CLD) for preterm infants. The key objectives are to: 1) characterize medical and social determinant profiles of preterm infants with CLD and identify high-risk groups, 2) describe the lived experiences of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $123,000 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Chicago to investigate the role of the Hedgehog (HH) signaling pathway in regulating progenitor cell differentiation during lung development and disease. The 2-year grant, which runs from February 2025 to November 2026, aims to: 1) decipher HH's temporal control over differentiation in mouse lungs, 2) characterize HH-receiving cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,057,973 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Johns Hopkins University to conduct research on modeling fetal lung development in congenital diaphragmatic hernia (CDH). The research aims to investigate the role of the YAP/TAZ mechanosensing pathway in CDH lung hypoplasia using mouse models, human lung organoids, and large animal fetal models. The research teams led by Shaun Kunisaki, Jason...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $740,317 to The Washington University in St. Louis to conduct research on the regulation of alveologenesis, the final phase of lung development, by FGF signaling pathways. The research aims to identify the cellular mechanisms by which FGF signaling regulates cell proliferation, differentiation, and death during the first and second stages...